Late Breaking Abstract - A Phase 1 trial to evaluate the safety, PK and target engagement of MTX-463, a monoclonal antibody inhibitor of WISP1
Year: 2025
Type: conference-abstract
Authors: Jeffrey Bornstein, Ahad Sabet, Gabriela Dower, Daniel Tavares, Chris Espelin, Colleen Graham, Daniel Beal, Rezi Zawadski, Kelly Regal, Ben Wilks, Allie Roach, Lin Ji, Saroj Nepal, Paul Yaworsky
Institution: Boston Foundation
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4416634280
Cites:
Cited by:
Related to: